NORDIC PHARMA
PharmaNORDIC PHARMA is a pharmaceutical company focused on Metabolic, Immunology, Cardiovascular.
NORDIC PHARMA at a Glance
- Fast trial execution (16 months median completion)
NORDIC PHARMA's Key Drugs
NORDIC PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
NORDIC PHARMA's Recent FDA Approvals
New NDA/BLA approvals for NORDIC PHARMA over the last two years — novel drugs only, excluding generics and label supplements.
NORDIC PHARMA's Therapeutic Areas
NORDIC PHARMA's approved drugs and pipeline span 3 therapeutic areas, led by Metabolic and Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NORDIC PHARMA's Top Competitors
NORDIC PHARMA's closest competitors by therapeutic-area and drug-target overlap include Sanofi, AstraZeneca, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NORDIC PHARMA Pipeline Snapshot
NORDIC PHARMA has 2 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 10/14 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1984-03-30
- Latest
- 2022-07-21
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges